伴有盆腔淋巴结转移的宫颈癌新辅助化疗联合放化疗临床疗效及预后因素分析

Treatment effect and analysis of prognostic factors of neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for advanced cervical cancer with pelvic lymph node metastasis

目的针对伴有盆腔淋巴结转移的中晚期宫颈鳞状细胞癌患者,回顾性分析新辅助化疗联合根治性同步放化疗及巩固化疗的临床疗效及预后影响因素。方法选取2015年1月—2018年1月就诊于蚌埠医学院第一附属医院的67例伴有盆腔淋巴结转移的宫颈鳞癌患者,分期为ⅡA~ⅢB期,研究组27例患者接受新辅助化疗联合同步放化疗及巩固化疗,对照组40例患者接受同步放化疗联合巩固化疗。观察2组患者的临床疗效、不良反应,用Kaplan-Meier法绘制的生存曲线,log-rank法比较预后,通过Cox回归模型进行多因素分析。结果在客观缓解率及3年无进展生存率方面,研究组明显高于对照组(88.9%vs.67.5%,P<0.05;70.4%vs.45.0%,P<0.05)。在3年总生存率方面,研究组稍高于对照组,但差异无统计学意义(77.8%vs.65.0%,P>0.05),2组在血液系统、消化系统、泌尿系统方面出现不良反应的情况,差异无统计学意义(均P>0.05)。Cox模型多因素分析显示,肿瘤分期、淋巴结转移部位是OS的独立影响因素,肿瘤分期、淋巴结转移部位、新辅助化疗是PFS的独立影响因素。结论对于伴有盆腔淋巴结转移的中晚期宫颈癌患者,新辅助化疗联合同步放化疗,再进行巩固化疗是一种有效的治疗方式,疗效优于直接进行同步放化疗后巩固化疗,且相关不良反应能够耐受。

Objective To evaluate the efficacy and prognostic factors of neoadjuvant chemotherapy followed by concurrent chemoradiotherapy of advanced cervical cancer patients with pelvic lymph node metastasis.Methods A total of 67 cases of advanced cervical cancer patients with pelvic lymph node metastasis(ⅡA-ⅢB)were collected in our hospital from January 2015 to January 2018.They were assigned to two groups:the treatment group(n=27)was treated with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy and consolidation chemotherapy,whilst the control group(n=40)only received concurrent chemoradiotherapy and consolidation chemotherapy.The clinical effect and related prognostic factors were observed.The survival curve was established via the Kaplan-Meier method.The survival of the two groups was compared via log-rank test.Multivariate Cox regression analysis was used for multivariate analysis.Results Compared with the control group,the treatment group showed improved objective response rate(88.9%vs.67.5%,P<0.05)and 3-year progression-free survival(PFS)rate(70.4%vs.45.0%,P<0.05).No significant difference was observed in the 3-year overall survival(OS)rate between the two groups(77.8%vs.65.0%,P>0.05).Bone marrow inhibition,gastrointestinal reactions and urinary system reactions were not significantly different in both groups(all P>0.05).Multivariate analysis showed that FIGO stage and location of lymph node metastasis were independent prognostic factors of OS.FIGO stage,location of lymph node metastasis and neoadjuvant chemotherapy were independent prognostic factors of PFS.Conclusion The addition of neoadjuvant chemotherapy to concurrent chemoradiotherapy and consolidation chemotherapy is superior to concurrent chemoradiotherapy and consolidation chemotherapy for advanced cervical cancer with pelvic lymph node metastasis.Moreover,the adverse reactions can be tolerated.